ArticleEvidence-based complementary and alternative medicine : eCAM2015
Oral Administration of Escin Inhibits Acute Inflammation and Reduces Intestinal Mucosal Injury in Animal Models.
Article in Evidence-based complementary and alternative medicine : eCAM, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Escin displays neuroprotective effects in mice with intracerebral hemorrhage through ameliorating intestinal injury.American journal of translational research · 2025Article
- Protective Effect of Escin Against Kidney Injury: Histopathological and Biochemical Evaluations.Current issues in molecular biology · 2024Article
- Escin's Action on Bradykinin Pathway: Advantageous Clinical Properties for an Unknown Mechanism?Antioxidants (Basel, Switzerland) · 2024Review
- Inhibitory effect of β-escin on Zika virus infection through the interruption of viral binding, replication, and stability.Scientific reports · 2023Article
- Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice.Frontiers in pharmacology · 2023Review
- Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Intestinal Flora-Derived Kynurenic Acid Protects Against Intestinal Damage Caused byFrontiers in microbiology · 2022Article
- Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines.Oncology reports · 2021Article
- Glucocorticoid-Like Activity of Escin: A New Mechanism for an Old Drug.Drug design, development and therapy · 2021Review
- The Use of Herbal Medicines for the Prevention of Glucocorticoid-Induced Osteoporosis.Frontiers in endocrinology · 2021Review
- β-Escin inhibits the proliferation of osteosarcoma cellsRSC advances · 2018Article
- Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-γ/NF-κB signal pathway.Oncotarget · 2017Article
- Involvement of galanin and galanin receptor 2 in nociceptive modulation in anterior cingulate cortex of normal rats and rats with mononeuropathy.Scientific reports · 2017Article
- Endothelia-Targeting Protection by Escin in Decompression Sickness Rats.Scientific reports · 2017Article
- Association of aescin with β- and γ-cyclodextrins studied by DFT calculations and spectroscopic methods.Beilstein journal of nanotechnology · 2017Article
- β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the effects of oral administration of escin on acute inflammation and intestinal mucosal injury in animal models. The effects of escin on carrageenan-induced paw edema in a rat model of acute inflammation, cecal ligation and puncture (CLP) induced intestinal mucosal injury in a mouse model, were observed. It was shown that oral administration of escin inhibits carrageenan-induced paw edema and decreases the production of prostaglandin E2 (PGE2) and cyclooxygenase- (COX-) 2. In CLP model, low dose of escin ameliorates endotoxin induced liver injury and intestinal mucosal injury and increases the expression of tight junction protein claudin-5 in mice. These findings suggest that escin effectively inhibits acute inflammation and reduces intestinal mucosal injury in animal models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.